Clinical Trials Logo

Neuralgia clinical trials

View clinical trials related to Neuralgia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06461312 Recruiting - Pudendal Neuralgia Clinical Trials

Combined PRF of the Pudendal Nerve With Ganglion Impar Block Effectively Alleviates Pudendal Neuralgia

PRF
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Patients with pudendal neuralgia suffer from long-term pain, which severely affects their quality of life. Due to unclear etiology, there is a lack of specific treatment methods. The aim of this study is to evaluate the efficacy of combined pulsed radiofrequency with ganglion impar block therapy helps evaluate the effectiveness of this treatment method for pudendal neuralgia, comparing it with traditional treatments or single interventions, and providing guidance for clinical practice.

NCT ID: NCT06459466 Recruiting - Clinical trials for Cervico-Brachial Neuralgia

Effects of Kinesiotherapy Exercises With Cervical Mobilization in Cervicobrachial Neuralgia

Start date: November 23, 2023
Phase: N/A
Study type: Interventional

To evaluate the effects of kinesiotherapy exercises with cervical mobilization in Cervicobrachial Neuralgia.

NCT ID: NCT06443281 Recruiting - Clinical trials for Spinal Cord Injuries

Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury

Start date: April 17, 2024
Phase:
Study type: Observational

The development of neuropathic pain is one of the most debilitating sequels after a spinal cord injury (SCI). The overall aim of this study is to investigate potential underlying pathophysiological mechanisms of neuropathic pain after SCI. The functionality of the nociceptive pathway in humans as well as its plastic changes following SCI will be inferred with sophisticated sensory and pain phenotyping using quantitative sensory testing (i.e., psychophysical measures), objective neurophysiological measures of pain processing and the recording of pain-related autonomic responses (i.e., galvanic skin response, cardiovascular measures and pupil dilation). In addition, the interplay between the somatosensory and autonomic nervous system and its association with the development and maintenance of neuropathic pain after SCI will be investigated.

NCT ID: NCT06438471 Recruiting - Clinical trials for Spinal Cord Injuries

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain. Researchers will compare EC5026 to placebo. Participants will be asked to: - Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days. - Undergo physical exams, vital signs assessments, ECGs, and blood draws - Complete assessments of pain, sleep, functional status, and perception of change

NCT ID: NCT06420778 Recruiting - Clinical trials for Postherpetic Neuralgia

A Randomized Controlled Study on the Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Based on the inclusion and exclusion criteria, patients with head and face PHN who met the requirements were selected as trial subjects, and the efficacy was clarified in a randomized controlled design trial. The visual analog score VAS was used as the primary evaluation index, and the depression self-assessment scale score , Hamilton depression scale, Pittsburgh sleep quality index scale, and quality of life evaluation scale (SF-36) were used as the secondary evaluation indexes, and oral pregabalin was used as the control group, and the subjects in the pregabalin and the plexus superficial stabbing combined with electroacupuncture groups were observed respectively at the time of Before treatment, immediately after the first treatment, after 2 days of treatment, after 2 weeks of treatment, after 4 weeks of treatment, after 1 month of follow-up after the end of treatment and after 2 months of follow-up after the end of treatment.

NCT ID: NCT06420141 Recruiting - Neuropathic Pain Clinical Trials

The Prevalence of Neuropathic Pain Pathophysiology Associated With Ankle Fracture

Start date: January 3, 2024
Phase:
Study type: Observational

This application addresses the Peer Reviewed Medical Research Program Investigator-Initiated Research Award FY21 W81XWH-22-CPMRP-IIRA area of Chronic Pain Management Research Program- The investigators will utilize subjects who have sustained ankle fractures and may develop chronic pain following bone union. No attempt will be made to affect the experimental outcome in the subjects. This study will adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of research.

NCT ID: NCT06413277 Recruiting - Chronic Pelvic Pain Clinical Trials

Targeting the Conus Medullaris With ECAP-Controlled Closed-Loop SCS for Treatment of Chronic Pelvic Pain: HOPE Trial

Start date: February 5, 2024
Phase:
Study type: Observational

The aim of the study is to evaluate the effectiveness of using ECAP (electrically evoked compound action potential)-controlled CL (closed-loop) SCS (spinal cord stimulation) to treat chronic pelvic pain by stimulating an area in the spine called the conus medullaris (the lowermost tapering extremity of the spinal cord).

NCT ID: NCT06407167 Recruiting - Neuropathic Pain Clinical Trials

Neuropathic Pain in Patients With Degenerative Lumbar Stenosis

Start date: May 13, 2024
Phase:
Study type: Observational

Pre- and postoperative pain in patients with degenerative stenosis requires great attention, as it can mislead the doctor about treatment tactics. Neuropathic pain in the legs before and after the surgical procedure, as well as the residual or recurrent pain syndrome existing against this background, overshadow the patient's recovery and cast doubt on the fullness of the performed decompression. Neural compression in the spinal canal and back pain may be the cause of the patient's antalgic posture and sagittal imbalance as seen on X-Ray, to need for corrective interventions surgical procedure. Thus, it is necessary to clarify the role and the influence of the pain and its type on the perioperative period in patients with degenerative lumbar spinal stenosis.

NCT ID: NCT06402448 Recruiting - Joint Pain Clinical Trials

Prevalence of Muscle and Nerve and Joint Pain

Start date: February 1, 2024
Phase:
Study type: Observational

The purpose of the study is to provide adequate information about the percentage of the main tissue that causing pain in most common spinal disorders either it is muscular, nerve or joint in each spinal parts, that will provide the physical therapist with large data that can be helpful in differential diagnosis.

NCT ID: NCT06357260 Recruiting - Clinical trials for Trigeminal Neuralgia

Pregabalin as an add-on Therapy to Carbamazepine in Trigeminal Neuralgia Patients

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Trigeminal neuralgia is a very painful condition associated with paroxysmal severe episodes of pain. Carbamazepine has been the first line of drug for Trigeminal Neuralgia. However, there are several adverse effects linked with Carbamazepine like drowsiness, accommodation disorders, hepatitis, derangement in hepatic enzymes, renal dysfunction. Pregabalin which is an established drug in neuropathic pain has better pharmacokinetic nature which allows for easy management and rapid dose escalation to therapeutic doses. There have been only few trials evaluating efficacy of Pregabalin in classical trigeminal neuralgia. Thus, the present study is designed to evaluate the efficacy of Pregabalin as an add-on therapy to carbamazepine in patients suffering from Trigeminal Neuralgia. In present trial 50 patients fulfilling the exclusion and inclusion criteria will be recruited in two arms that is test group and the control group. The test group will be prescribed carbamazepine along with fixed dose of Pregabalin 75mg twice daily while the control group will be prescribed carbamazepine only. The dose of carbamazepine will be titrated in both groups as per patients need. The outcome regarding pain relief, quality of life and adverse effects and mean dose of carbamazepine required in both groups will be evaluated.